[{"@odata.etag":"\"3\"","ItemInternalId":"1","ID":1,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Institution#Id":0,"StudyName":"REMODEL-2","Description":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"William L. Conte, MD, MS","StudyContact":"Michelle Ham, RN","StudyContact0":"mham@methodisthospitals.org","Link":"https://clinicaltrials.gov/study/NCT05156281?cond=Multiple%20Sclerosis&intr=remibrutinib&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f1_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=1&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/1_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"2","ID":2,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Institution#Id":0,"StudyName":"FREXALT","Description":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"William L. Conte, MD, MS","StudyContact":"Michelle Ham, RN","StudyContact0":"mham@methodisthospitals.org","Link":"https://clinicaltrials.gov/study/NCT06141473?cond=Multiple%20Sclerosis&intr=frexalimab&rank=2","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f2_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=2&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/2_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"3","ID":3,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Institution#Id":0,"StudyName":"FREVIVA","Description":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Progressive MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,2],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"William L. Conte, MD, MS","StudyContact":"Michelle Ham, RN","StudyContact0":"mham@methodisthospitals.org","Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f3_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=3&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/3_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"4","ID":4,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Institution#Id":1,"StudyName":"SOSTOS","Description":"A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels.","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Carolyn Goldschmidt, DO","StudyContact":"May Navamon Aunaetitrakul","StudyContact0":" naunaetitrakul@northshore.org","Link":"https://clinicaltrials.gov/study/NCT05090371?term=SOSTOS&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f4_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=4&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/4_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"5","ID":5,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Institution#Id":1,"StudyName":"FREXALT","Description":"Master protocol of two Phase 3, randomized, double-blind efficacy and safety studies comparing frexalimab (SAR441344) to teriflunomide (Aubagio) in adult participants with relapsing forms of multiple sclerosis.","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Afif Hentati, MD","StudyContact":"May Navamon Aunaetitrakul","StudyContact0":"naunaetitrakul@northshore.org","Link":"https://clinicaltrials.gov/study/NCT06141473?cond=Multiple%20Sclerosis&intr=frexalimab&rank=2","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f5_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=5&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/5_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"6","ID":6,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Institution#Id":1,"StudyName":"OPTIS","Description":"Performance and safety of a digital tool for the unsupervised self-assessment of neuromyelitis optica spectrum disorder.","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"NMOSD"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[5],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Afif Hentati, MD","StudyContact":"Martha Cruz","StudyContact0":"mcruz8@northshore.org","Link":"https://clinicaltrials.gov/study/NCT05566769?term=OPTIS&rank=3","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f6_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=6&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/6_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"7","ID":7,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Institution#Id":1,"StudyName":"ENABLE","Description":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Carolyn Goldschmidt, DO","StudyContact":"May Navamon Aunaetitrakul","StudyContact0":"naunaetitrakul@northshore.org","Link":"https://clinicaltrials.gov/study/NCT06433752?term=ENABLE&intr=Ublituximab&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f7_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=7&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/7_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"8","ID":8,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"REMODEL-2","Description":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Tom Shoemaker, MD","StudyContact":"Becca McWilliams ","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT05156281?cond=Multiple%20Sclerosis&intr=remibrutinib&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f8_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=8&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/8_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"9","ID":9,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"TREAT-MS","Description":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Tom Shoemaker, MD ","StudyContact":"Becca McWilliams ","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT03500328?term=TREAT-MS&rank=2","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f9_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=9&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/9_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"10","ID":10,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"FREVIVA","Description":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Progressive MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,2],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Tom Shoemaker, MD","StudyContact":"Becca McWilliams ","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f10_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=10&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/10_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"11","ID":11,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"OAK","Description":"Comparison Between ABP 692 and Ocrevus","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[1,0],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Tom Shoemaker, MD","StudyContact":"Becca McWilliams ","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT06700343?term=Comparison%20Between%20ABP%20692%20and%20Ocrevus&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f11_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=11&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/11_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"12","ID":12,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"ENHANCE","Description":"Study to Evaluate Efficacy of a Modified Regimen of Ublituximab","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[1,0],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Tom Shoemaker, MD","StudyContact0":"elizabeth_dvorak@rush.edu","Link":"https://clinicaltrials.gov/study/NCT05877963?term=enhance&intr=Ublituximab&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f12_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=12&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/12_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"13","ID":13,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"ENABLE","Description":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Fabian Sierra-Morales, MD","StudyContact":"Becca McWilliams","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT06433752?term=ENABLE&intr=Ublituximab&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f13_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=13&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/13_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"14","ID":14,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Institution#Id":2,"StudyName":"CLOU064C12306","Description":"A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib.","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Allison Osen, MD","StudyContact":"Becca McWilliams ","StudyContact0":"rebecca_mcwilliams@rush.edu","Link":"https://clinicaltrials.gov/study/NCT06846281?term=efficacy%20and%20safety%20of%20remibrutinib%20after%20switching&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f14_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=14&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/14_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"15","ID":15,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Institution#Id":3,"StudyName":"KATHAROS","Description":"Effect of Kesimpta in lactating women with MS","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Edith Graham, MD","StudyContact":"Irena Bellinski, RN","StudyContact0":"irena.bellinski@nm.org","Link":"https://clinicaltrials.gov/study/NCT06444113?term=katharos&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f15_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=15&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/15_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"16","ID":16,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Institution#Id":3,"StudyName":"BEAT-MS","Description":"Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Relapsing MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,1],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Dr. George Georges","StudyContact":"Matthew Selle","StudyContact0":"matthew.selle@nm.org","Link":"https://clinicaltrials.gov/study/NCT04047628?term=beat-ms&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f16_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=16&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/16_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"17","ID":17,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Institution#Id":3,"StudyName":"ExTINGUISH","Description":"Trial of Inebilizumab in NMDAR Encephalitis ","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":4,"Value":"Autoimmune Encephalitis"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[4],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Dr. Elena Grebenciucova","StudyContact":"Monika Szela ","StudyContact0":"monika.szela@northwestern.edu","Link":"https://clinicaltrials.gov/study/NCT04372615?term=ExTINGUISH%20Trial%20of%20Inebilizumab%20in%20NMDAR%20Encephalitis%20&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f17_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=17&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/17_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"18","ID":18,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":4,"Value":"The University of Chicago"},"Institution#Id":4,"StudyName":"FREVIVA","Description":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Progressive MS"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,2],"ConditionTag#Id@odata.type":"#Collection(Int64)","PI":"Dr. Veronica Cipriani","Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f18_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=18&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/18_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"19","ID":19,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"StudyName":"METS for MS","Description":"Mood and Exercise Training Study for Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Alison Wathen","StudyContact0":"awathe2@uic.edu","Link":"https://metsforms.ahs.uic.edu/","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f19_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=19&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/19_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"20","ID":20,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"StudyName":"PACE MS","Description":"Cognition, Vascular Function, and Physical Activity in Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Peixuan Zheng","StudyContact0":"pacems@uic.edu","Link":"https://go.uic.edu/pacems","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f20_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=20&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/20_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"21","ID":21,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"Description":"Walking Efficiency and Vascular Function in Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Brenda Jeng","StudyContact0":"enrl@uic.edu","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f21_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=21&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/21_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"22","ID":22,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"Description":"Randomized Pilot Study Evaluating the Effect of a 6-Month Exercise Rehabilitation Program on Physical and Cognitive Function in Persons with MS who Use Wheelchairs as a Primary Mobility Device","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Ilaria Santi","StudyContact0":"isanti@uic.edu","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f22_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=22&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/22_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"23","ID":23,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"StudyName":"REAL MS","Description":"Race, Ethnicity, and Active Lifestyle in MS","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Victoria Flores","StudyContact0":"realms@uic.edu","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f23_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=23&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/23_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"24","ID":24,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"StudyName":"BIPAMS-C","Description":"Behavioral Intervention for Physical Activity in Multiple Sclerosis – Cognition","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Emily Barron","StudyContact0":"bipamscognition@uic.edu","Link":"https://bipamscognition.ahs.uic.edu/","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f24_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=24&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/24_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"25","ID":25,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"StudyName":"PAW-MS-GAD","Description":"Physical Activity in Women with Multiple Sclerosis and Generalized Anxiety Disorder","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Petra Silic","StudyContact0":"enrl@uic.edu","Link":"https://www.redcap.ihrp.uic.edu/surveys/?s=4DWDHMY8MC8DDHNL","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f25_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=25&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/25_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"},{"@odata.etag":"\"3\"","ItemInternalId":"26","ID":26,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Institution#Id":5,"Description":"Knowledge and Perceptions of Exercise Training Among People Living with Multiple Sclerosis","ConditionTag":[{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"MS"},{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Exercise Physiology"}],"ConditionTag@odata.type":"#Collection(Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference)","ConditionTag#Id":[0,3],"ConditionTag#Id@odata.type":"#Collection(Int64)","StudyContact":"Louise Declerck","StudyContact0":"enrl@uic.edu","Active_x003f_":true,"{Identifier}":"Lists%252fResearch%2bClinical%2bTrials%252f26_.000","{IsFolder}":false,"{Thumbnail}":{"Large":null,"Medium":null,"Small":null},"{Link}":"https://chicagoms.sharepoint.com/sites/ChicagoMSAllianceResearch/_layouts/15/listform.aspx?PageType=4&ListId=dc12c2ec%2Dc90b%2D475d%2Db456%2D9fc3d2ba4cd5&ID=26&ContentTypeID=0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{Name}":"","{FilenameWithExtension}":"","{Path}":"Lists/Research Clinical Trials/","{FullPath}":"Lists/Research Clinical Trials/26_.000","{ModerationStatus}":"Approved","{ContentType}":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedContentType","Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","Name":"Item"},"{ContentType}#Id":"0x0100BB435CB09F2EEB48A3C8AC60BB42744F003A57BB02064601409452CC619F5D696E","{HasAttachments}":false,"{VersionNumber}":"2.0"}]